» Articles » PMID: 35365073

Cardiovascular Health in Pediatric Heart Transplant Patients

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ideal "cardiovascular health" (CVH)-optimal diet, exercise, nonsmoking, BMI, BP, lipids, and glucose-is associated with healthy longevity in adults. Pediatric heart transplant (HT) patients may be at risk for suboptimal CVH.

Methods: Single-center retrospective study of HT patients 2003-2014 who survived 1 year post-transplant. Five CVH metrics were collected at listing, 1, 3 and 5 years post-transplant (diet and exercise were unavailable). CVH was scored by summing individual metrics: ideal = 2, intermediate = 1, and poor = 0 points; total scores of 8-10 points were considered high (favorable). CVH was compared between HT patients and the US pediatric population (GP) utilizing NHANES 2007-2016. Logistic regression was performed to examine the association of CVH 1 year post-transplant with a composite adverse outcome (death, re-listing, coronary vasculopathy, or chronic kidney disease) 3 years post-transplant.

Results: We included 110 HT patients (median age at HT: 6 years [range 0.1-21]) and 19,081 NHANES participants. CVH scores among HT patients were generally high at listing (75%), 1 (74%), 3 (87%) and 5 (76%) years post-transplant and similar to GP, but some metrics (e.g., glucose) were worse among HT patients. Among HT patients, CVH was poorer with older age and non-Caucasian race/ethnicity. Per 1-point higher CVH score, the demographic-adjusted OR for adverse outcomes was 0.95 (95% CI, 0.7-1.4).

Conclusions: HT patients had generally favorable CVH, but some metrics were unfavorable and CVH varied by age and race/ethnicity. No significant association was detected between CVH and adverse outcomes in this small sample, but study in a larger sample is warranted.

Citing Articles

Racial disparity exists in the utilization and post-transplant survival benefit of ventricular assist device support in children.

Greenberg J, Bryant 3rd R, Villa C, Fields K, Fynn-Thompson F, Zafar F J Heart Lung Transplant. 2023; 42(5):585-592.

PMID: 36710094 PMC: 10121747. DOI: 10.1016/j.healun.2022.12.020.

References
1.
Kindel S, Law Y, Chin C, Burch M, Kirklin J, Naftel D . Improved Detection of Cardiac Allograft Vasculopathy: A Multi-Institutional Analysis of Functional Parameters in Pediatric Heart Transplant Recipients. J Am Coll Cardiol. 2015; 66(5):547-57. DOI: 10.1016/j.jacc.2015.05.063. View

2.
Kindel S, Pahl E . Current therapies for cardiac allograft vasculopathy in children. Congenit Heart Dis. 2012; 7(4):324-35. DOI: 10.1111/j.1747-0803.2012.00666.x. View

3.
Cordero Fort A, Gavira J, Alegria-Barrero E, Castano S, Martin A, Ubilla M . Prevalence of metabolic syndrome in heart transplant patients: role of previous cardiopathy and years since the procedure--the TRACA study. J Heart Lung Transplant. 2006; 25(10):1192-8. DOI: 10.1016/j.healun.2006.06.012. View

4.
Pahl E . Statins in the prevention of transplant coronary artery disease: in pediatric heart recipients. Pediatr Transplant. 2007; 11(5):459-60. DOI: 10.1111/j.1399-3046.2007.00710.x. View

5.
Rossano J, Cherikh W, Chambers D, Goldfarb S, Hayes Jr D, Khush K . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric heart transplantation report-2018; Focus theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018; 37(10):1184-1195. DOI: 10.1016/j.healun.2018.07.018. View